Connect Biopharma (CNTB) Noble Capital Markets Emerging Growth Virtual Equity Conference summary

Strategic focus and management changes

• New management team with extensive drug development and FDA experience was brought in last year to lead a new chapter focused on rademikibart.

• Headquarters relocated to San Diego, reducing China footprint to become more U.S.-centric.

• Shifted focus to acute exacerbations in asthma and COPD, targeting a unique market opportunity.

• Cash runway extends into 2027, supporting ongoing and planned studies.

• Recent SEC filings and cash position of nearly $84 million as of March.

Clinical development and product differentiation

• Two parallel phase 2 studies initiated for acute asthma and COPD exacerbations, with all planned studies now ongoing.

• Rademikibart demonstrated rapid and profound FEV1 improvements, with most benefit seen within 24 hours.

• No other biologic is approved for acute exacerbations; current biologics are not indicated for acute use.

• Product shows a differentiated safety profile, reducing eosinophil counts compared to Dupixent.

• Opportunity for Q4 week dosing, potentially offering greater convenience than competitors.

Market opportunity and health economics

• Acute indication could unlock a $5 billion+ global market, with over 2 million U.S. emergency visits annually for asthma/COPD exacerbations.

• 50% of patients experience worsening or a second event within four weeks of an acute episode.

• Hospitals face financial losses on these patients; reducing length of stay and readmissions could yield significant cost savings.

• Emergency room reimbursement averages $4,000 per visit; hospital stays are more costly.

• Plans for a low-cost hospital product to fit within DRG reimbursement structures.